NO175704C - Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon - Google Patents

Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon

Info

Publication number
NO175704C
NO175704C NO874445A NO874445A NO175704C NO 175704 C NO175704 C NO 175704C NO 874445 A NO874445 A NO 874445A NO 874445 A NO874445 A NO 874445A NO 175704 C NO175704 C NO 175704C
Authority
NO
Norway
Prior art keywords
preparation
stable pharmaceutical
recombinant interferon
ionic polymeric
biocompatible non
Prior art date
Application number
NO874445A
Other languages
English (en)
Other versions
NO874445D0 (no
NO175704B (no
NO874445L (no
Inventor
Ze Ev Shaked
Tracy Stewart
Jody Thomson
James William Thomson
Terrance Taford
Susan Hershenson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of NO874445D0 publication Critical patent/NO874445D0/no
Publication of NO874445L publication Critical patent/NO874445L/no
Publication of NO175704B publication Critical patent/NO175704B/no
Publication of NO175704C publication Critical patent/NO175704C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO874445A 1986-10-27 1987-10-26 Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon NO175704C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92342386A 1986-10-27 1986-10-27

Publications (4)

Publication Number Publication Date
NO874445D0 NO874445D0 (no) 1987-10-26
NO874445L NO874445L (no) 1988-04-28
NO175704B NO175704B (no) 1994-08-15
NO175704C true NO175704C (no) 1994-11-23

Family

ID=25448670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO874445A NO175704C (no) 1986-10-27 1987-10-26 Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon

Country Status (9)

Country Link
EP (1) EP0270799B1 (no)
JP (1) JPS63179833A (no)
AT (1) ATE111744T1 (no)
AU (2) AU8019187A (no)
CA (1) CA1294215C (no)
DE (1) DE3750574T2 (no)
DK (1) DK563487A (no)
FI (1) FI95002C (no)
NO (1) NO175704C (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
PT1017413E (pt) 1997-09-23 2003-02-28 Rentschler Biotech Gmbh Formulacoes liquidas de interferao (beta)
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
DE60139339D1 (de) 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
ATE473016T1 (de) 2003-11-04 2010-07-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
NZ702146A (en) 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CN105263390A (zh) 2013-04-23 2016-01-20 雪松-西奈医学中心 用于从荧光团同时录制可见光图像和红外光图像的系统和方法
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
MX2016016507A (es) 2014-06-12 2017-04-27 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
KR101799557B1 (ko) 2014-07-22 2017-11-20 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
WO2016073647A2 (en) 2014-11-04 2016-05-12 University Of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
AU2016258984B2 (en) 2015-05-05 2020-11-19 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2017040594A1 (en) 2015-08-31 2017-03-09 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset alzheimer's disease
WO2017138925A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Antitumour combinations of antisense oligonucleotides and anticancer agents
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
SG11201907260PA (en) 2017-02-06 2019-09-27 Lemonex Inc Physiologically active substance carrier
WO2019023245A1 (en) 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
US11529338B2 (en) 2017-08-22 2022-12-20 Cedars-Sinai Medical Center Compositions and methods for treating cancer
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
BR112020020159A2 (pt) * 2018-04-19 2021-01-05 Lts Lohmann Therapie-Systeme Ag Sistema de microagulhas para a aplicação de interferon
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
US20210395358A1 (en) 2018-11-08 2021-12-23 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
AU2019404553A1 (en) 2018-12-20 2021-06-24 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55102519A (en) * 1979-01-31 1980-08-05 Green Cross Corp:The Stabilization of interferon
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
ATE52693T1 (de) * 1982-10-25 1990-06-15 Genentech Inc Synergistische humaninterferonaktivitaet.
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物

Also Published As

Publication number Publication date
JPS63179833A (ja) 1988-07-23
NO874445D0 (no) 1987-10-26
AU8019187A (en) 1988-04-28
CA1294215C (en) 1992-01-14
DK563487A (da) 1988-04-28
FI874706A0 (fi) 1987-10-26
NO175704B (no) 1994-08-15
DE3750574T2 (de) 1995-02-02
FI95002C (fi) 1995-12-11
EP0270799A1 (en) 1988-06-15
EP0270799B1 (en) 1994-09-21
AU659127B2 (en) 1995-05-11
DK563487D0 (da) 1987-10-27
AU1063392A (en) 1992-03-19
ATE111744T1 (de) 1994-10-15
DE3750574D1 (de) 1994-10-27
FI95002B (fi) 1995-08-31
NO874445L (no) 1988-04-28
FI874706A (fi) 1988-04-28

Similar Documents

Publication Publication Date Title
NO175704C (no) Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
NO179479C (no) Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ATE106247T1 (de) Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung.
DK1381432T3 (da) HSA-frie interferon-beta-præparater
SE8402560D0 (sv) Farmaceutisk komposition
ATE361093T1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
NO993121D0 (no) Stabile flytende interferon-formuleringer
DK0759775T3 (da) Flydende IFN-beta-formuleringer
ATE126063T1 (de) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen.
YU184090A (sh) Stabilizovani interferoni leukocita
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
NO301805B1 (no) Fremgangsmåte for fremstilling av et stabilt, galenisk, vandig preparat av erytropoietin
IT8522442A0 (it) Derivati nucleosidici aventi proprieta' antierpetiche, composizioni farmaceutiche che licontengono e procedimento per lapreparazione degli ingredienti attivi.

Legal Events

Date Code Title Description
MK1K Patent expired